letrozole + human chorionic gonadotrophin

Letrozole + human chorionic gonadotrophin is a combination therapy used primarily in reproductive medicine for ovulation induction and infertility treatment. Letrozole is an aromatase inhibitor that reduces estrogen synthesis by inhibiting the conversion of androgens to estrogens, leading to increased release of follicle-stimulating hormone (FSH) from the pituitary gland. This promotes follicular development in the ovaries. Human chorionic gonadotrophin (hCG) is a hormone that mimics luteinizing hormone (LH), triggering final oocyte maturation and ovulation when administered during controlled ovarian stimulation cycles. This combination has been studied for use in women with polycystic ovary syndrome (PCOS) who are resistant to clomiphene citrate, as well as in intrauterine insemination (IUI) cycles for unexplained infertility. The addition of letrozole can reduce the required dose of exogenous gonadotropins such as FSH or HMG, lower the risk of ovarian hyperstimulation syndrome (OHSS), improve endometrial thickness, and maintain or improve pregnancy rates compared to monotherapy with either agent[1][3][4]. In men with idiopathic infertility—especially those who are obese—the combination may improve sperm parameters more effectively than either drug alone[5].

Other names

letrozole and hCGletrozole plus human chorionic gonadotropinLTZ + hCG